Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel

被引：1
作者：
Mian, Agrima [1 ]
Wei, Wei [2 ]
Hamilton, Betty K. [3 ]
Winter, Allison M. [3 ]
Khouri, Jack [3 ]
Pohlman, Brad [3 ]
Gerds, Aaron T. [3 ]
Jagadeesh, Deepa [3 ]
Anwer, Faiz [3 ]
Kalaycio, Matt [3 ]
Dean, Robert M. [3 ]
Sobecks, Ronald [3 ]
Caimi, Paolo F. [3 ]
Hill, Brian T. [3 ]
Majhail, Navneet S. [4 ]
机构：
[1] Cleveland Clin, Dept Internal Med, Cleveland, OH USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA
[3] Cleveland Clin, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH USA
[4] Sarah Cannon, Nashville, TN 37203 USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / 05期
关键词：
TRANSPLANTATION; OUTCOMES; THERAPY;
D O I：
10.1038/s41409-023-01934-4
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：590 / 593
页数：4
相关论文
共 50 条
  • [41] Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
    Nastoupil, Loretta J.
    Jain, Michael D.
    Feng, Lei
    Spiegel, Jay Y.
    Ghobadi, Armin
    Lin, Yi
    Dahiya, Saurabh
    Lunning, Matthew
    Lekakis, Lazaros
    Reagan, Patrick
    Oluwole, Olalekan
    McGuirk, Joseph
    Deol, Abhinav
    Sehgal, Alison R.
    Goy, Andre
    Hill, Brian T.
    Vu, Khoan
    Andreadis, Charalambos
    Munoz, Javier
    Westin, Jason
    Chavez, Julio C.
    Cashen, Amanda
    Bennani, N. Nora
    Rapoport, Aaron P.
    Vose, Julie M.
    Miklos, David B.
    Neelapu, Sattva S.
    Locke, Frederick L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3119 - +
  • [42] Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report
    Fenton, Graeme A.
    Dean, Erin A.
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 75 - 81
  • [43] Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma A Review
    Locke, Frederick L.
    Go, William Y.
    Neelapu, Sattva S.
    JAMA ONCOLOGY, 2020, 6 (02) : 281 - 290
  • [44] Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience
    Ghafouri, Sanaz
    Fenerty, Kathleen
    Schiller, Gary
    de Vos, Sven
    Eradat, Herbert
    Timmerman, John
    Larson, Sarah
    Mead, Monica
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12) : 861 - 872
  • [45] Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
    Jacobson, Caron A.
    Locke, Frederick L.
    Ma, Long
    Asubonteng, Julius
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Ahmed, Sairah
    Ghobadi, Armin
    Miklos, David Bernard
    Lin, Yi
    Perales, Miguel-Angel
    Lunning, Matthew Alexander
    Herr, Megan M.
    Hill, Brian T.
    Ganguly, Siddhartha
    Dong, Hua
    Nikiforow, Sarah
    Hooper, Michele
    Kawashima, Jun
    Xu, Hairong
    Pasquini, Marcelo C.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (09): : 581.e1 - 581.e8
  • [46] Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Jousseaume, Etienne
    Yang, Hongbo
    Chai, Xinglei
    Xiang, Cheryl
    Wang, Travis
    Zhang, Jie
    Ramos, Roberto
    Schuster, Stephen J.
    Fowler, Nathan
    LEUKEMIA & LYMPHOMA, 2024, 65 (03) : 323 - 332
  • [47] Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
    Maziarz, Richard T.
    Zhang, Jie
    Yang, Hongbo
    Chai, Xinglei
    Yuan, Chengbo
    Schwarz, Elisabeth
    Jakovac, Mihael
    Martinez-Prieto, Marcela
    Agarwal, Abhijit
    Degtyarev, Evgeny
    Tam, Constantine
    Salles, Gilles
    BLOOD ADVANCES, 2022, 6 (08) : 2536 - 2547
  • [48] Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
    Locke, Frederick L.
    Ghobadi, Armin
    Jacobson, Caron A.
    Miklos, David B.
    Lekakis, Lazaros J.
    Oluwole, Olalekan O.
    Lin, Yi
    Braunschweig, Ira
    Hill, Brian T.
    Timmerman, John M.
    Deol, Abhinav
    Reagan, Patrick M.
    Stiff, Patrick
    Flinn, Ian W.
    Farooq, Umar
    Goy, Andre
    McSweeney, Peter A.
    Munoz, Javier
    Siddiqi, Tanya
    Chavez, Julio C.
    Herrera, Alex F.
    Bartlett, Nancy L.
    Wiezorek, Jeffrey S.
    Navale, Lynn
    Xue, Allen
    Jiang, Yizhou
    Bot, Adrian
    Rossi, John M.
    Kim, Jenny J.
    Go, William Y.
    Neelapu, Sattva S.
    LANCET ONCOLOGY, 2019, 20 (01) : 31 - 42
  • [49] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
    Qi, Cynthia Z.
    Bollu, Vamsi
    Yang, Hongbo
    Dalal, Anand
    Zhang, Su
    Zhang, Jie
    CLINICAL THERAPEUTICS, 2021, 43 (08) : 1300 - +
  • [50] Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Ghobadi, Armin
    Miklos, David B.
    Lekakis, Lazaros J.
    Oluwole, Olalekan O.
    Lin, Yi
    Braunschweig, Ira
    Hill, Brian T.
    Timmerman, John M.
    Deol, Abhinav
    Reagan, Patrick M.
    Stiff, Patrick
    Flinn, Ian W.
    Farooq, Umar
    Goy, Andre H.
    McSweeney, Peter A.
    Munoz, Javier
    Siddiqi, Tanya
    Chavez, Julio C.
    Herrera, Alex F.
    Bartlett, Nancy L.
    Bot, Adrian A.
    Shen, Rhine R.
    Dong, Jinghui
    Singh, Kanwarjit
    Miao, Harry
    Kim, Jenny J.
    Zheng, Yan
    Locke, Frederick L.
    BLOOD, 2023, 141 (19) : 2307 - 2315
12345